La cadena de opciones muestra datos clave de las opciones de acciones de ProPhase Labs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ProPhase Labs..

ProPhase Labs (NASDAQ:PRPH) Bolsa, Cadena de Opciones

ProPhase Labs

ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.

ProPhase Labs Inc

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 73.1% to $0.8 during Friday's regular session. The company's market cap stands at $9.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock rose 43.62% to $34.9. The market value of their outstanding shares is at $454.1 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock rose 37.05% to $0.52. The company's market cap stands at $1.7 million. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares rose 32.04% to $1.88. The company's market cap stands at $111.6 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock moved upwards by 23.95% to $3.57. The market value of their outstanding shares is at $54.3 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares moved upwards by 22.34% to $1.15. The company's market cap stands at $15.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NeuroOne Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMTC#NASDAQ">NMTC</a>) stock declined by 44.3% to $0.48 during Friday's regular session. The market value of their outstanding shares is at $14.7 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares fell 32.16% to $1.35. The market value of their outstanding shares is at $1.9 million. </li>
<li>Lifecore Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) stock fell 22.62% to $5.27. The company's market cap stands at $195.1 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 22.2% to $0.27. The company's market cap stands at $8.1 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock declined by 22.11% to $0.44. The market value of their outstanding shares is at $2.3 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) shares decreased by 20.6% to $0.26. The market value of their outstanding shares is at $66.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADAP

ALDX

APVO

KAPA

LFCR

NIVF

NMTC

PRPH

RSLS

12 Health Care Stocks Moving In Friday's Intraday Session

WIIM

ProPhase Labs shares are trading lower after the compant reported worse-than-expected FY24 financial results.

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) reported FY24 losses of $(2.61) per share which missed the analyst consensus estimate of $(1.27) by 105.51 percent. This is a 411.76 percent decrease over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $6.80 million which missed the analyst consensus estimate of $13.02 million by 47.77 percent. This is a 56.29 percent increase over sales of $4.35 million the same period last year.

Earnings

Earnings Misses

News

ProPhase Labs FY24 EPS $(2.61) Misses $(1.27) Estimate, Sales $6.80M Miss $13.02M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) is estimated to report quarterly loss at $1.36 per share on revenue of $2.69 million. 
• ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) is likely to report quarterly loss at $0.24 per share on revenue of $3.77 million. 
• Synergy CHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNYR#NASDAQ">SNYR</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $10.55 million. 
• Westport Fuel Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WPRT#NASDAQ">WPRT</a>) is estimated to report quarterly loss at $0.28 per share on revenue of $70.35 million. 
• Loar Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $102.51 million. 
• Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) is expected to report earnings for its fourth quarter. 
• Edible Garden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) is estimated to report quarterly loss at $9.00 per share on revenue of $4.12 million. 
• Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $16.98 million. 
• Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) is expected to report earnings for its fourth quarter. 
• FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) is projected to report quarterly loss at $0.84 per share on revenue of $11.61 million. 
• Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $77.16 million. 
• Workhorse Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) is expected to report quarterly loss at $4.38 per share on revenue of $3.06 million. 
• LM Funding America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) is estimated to report quarterly loss at $1.67 per share on revenue of $1.50 million. 
• Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $6.20 million. 
• BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $7.72 million. 
• IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.39 per share on revenue of $10.43 million. 
• LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) is expected to report quarterly loss at $0.14 per share on revenue of $23.55 million. 
• Palvella Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) is likely to report earnings for its fourth quarter. 
• Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) is expected to report quarterly loss at $0.15 per share on revenue of $3.80 million. 
• Chicago Atlantic BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIEN#NASDAQ">LIEN</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $11.00 million. 
• BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is likely to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• T Stamp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDAI#NASDAQ">IDAI</a>) is projected to report quarterly loss at $1.80 per share on revenue of $510 thousand. 
• Local Bounti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOCL#NYSE">LOCL</a>) is expected to report quarterly loss at $3.89 per share on revenue of $10.95 million. 
• Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) is estimated to report quarterly loss at $0.43 per share on revenue of $3.89 million. 
• Siyata Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) is projected to report earnings for its fourth quarter. 
• Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $24.03 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) is expected to report earnings for its fourth quarter. 
• CXApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $2.00 million. 
• Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is projected to report earnings for its fourth quarter. 
• Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) is projected to report earnings for its Fiscal Year 2024. 
• Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is expected to report earnings for its fourth quarter. 
• Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) is estimated to report earnings for its fourth quarter. 
• Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $92.50 million. 
• Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $3.90 million. 
• Red Cat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) is projected to report quarterly loss at $0.09 per share on revenue of $7.49 million. 
• Digi Power X (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGXX#NASDAQ">DGXX</a>) is likely to report quarterly loss at $0.12 per share on revenue of $14.30 million. 
• Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) is projected to report earnings for its fourth quarter. 
• Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) is likely to report earnings for its fourth quarter. 
• VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $545 thousand. 
• iShares Gold Trust Shares of the iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>) is projected to report quarterly loss at $0.02 per share on revenue of $37.70 million. 
• i-80 Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IAUX#AMEX">IAUX</a>) is projected to report earnings for its fourth quarter. 
• Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) is expected to report earnings for its fourth quarter. 
• Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter. 
• MDB Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDBH#NASDAQ">MDBH</a>) is estimated to report earnings for its fourth quarter. 
• Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) is expected to report quarterly loss at $0.34 per share on revenue of $1.60 million. 
• Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is likely to report quarterly loss at $0.63 per share on revenue of $1.00 million. 
• Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) is projected to report earnings for its fourth quarter. 
• CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) is likely to report quarterly loss at $0.07 per share on revenue of $9.43 million. 
• Venu Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VENU#AMEX">VENU</a>) is expected to report earnings for its fourth quarter. 
• Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) is estimated to report earnings for its fourth quarter. 
• ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) is projected to report quarterly loss at $1.33 per share on revenue of $6.30 million. 
• Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) is estimated to report earnings for its fourth quarter. 
• Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is projected to report earnings for its fourth quarter. 
• Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.96 per share on revenue of $1.70 million. 
• CaliberCos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>) is likely to report quarterly loss at $0.04 per share on revenue of $6.69 million. 
• Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) is expected to report earnings for its fourth quarter. 
• Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) is projected to report quarterly earnings at $1.39 per share on revenue of $234.69 million. 
• PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) is likely to report quarterly earnings at $3.24 per share on revenue of $2.34 billion. 
• Invesco National AMT-Free Municipal Bond ETFo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZA#NYSE">PZA</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $168.10 million. 
• BioHarvest Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) is likely to report earnings for its fourth quarter. 
• Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) is projected to report quarterly loss at $0.01 per share on revenue of $212.30 million. 
• Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) is expected to report quarterly loss at $8.40 per share on revenue of $6.30 million. 
• Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) is likely to report earnings for its fourth quarter. 
• TechTarget (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTGT#NASDAQ">TTGT</a>) is expected to report quarterly earnings at $0.45 per share on revenue of $62.37 million. 
• Rekor Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) is expected to report quarterly loss at $0.08 per share on revenue of $12.91 million. 
• Flexible Solutions Intl (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSI#AMEX">FSI</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $10.83 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOG

AQMS

BCLI

BHST

BLRX

BNGO

BOSC

CELC

CRIS

CTSO

CXAI

DARE

DGXX

DTST

DUOT

EDBL

FTCI

GORV

GRRR

GRYP

IAUX

IDAI

IMCC

LIEN

LMFA

LNZA

LOAR

LOCL

LPRO

MDBH

MVST

NNOX

NSYS

NUTX

NVVE

OMER

PRGS

PRPO

PVLA

PowerShares Insured Municipal Bond Portfolio

RANI

RCAT

REKR

SGML

SIDU

SNYR

SPIR

Spruce Power Holding Corporation Class A Common Stock

SPRU

SYTA

TLPH

TTGT

VATE

VENU

VERO

VNRX

VVOS

WKHS

WPRT

WRAP

XPON

Earnings Scheduled For March 31, 2025

ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) will release its quarterly earnings report on Monday, 2025-03-31. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate ProPhase Labs to report an earnings per share (EPS) of $-0.24.
The market awaits ProPhase Labs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.39, leading to a 2.42% drop in the share price on the subsequent day.
Here's a look at ProPhase Labs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.04</td>
<td>-0.24</td>
<td>-0.28</td>
<td>-0.26</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.35</td>
<td>-0.33</td>
<td>-0.07</td>
<td>-0.51</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-10.0%</td>
<td>3.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1743181361_0.png" alt="eps graph" />
<h3>Performance of ProPhase Labs Shares</h3>
Shares of ProPhase Labs were trading at $0.46 as of March 27. Over the last 52-week period, shares are down 93.76%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/PRPH/earnings">To track all earnings releases for ProPhase Labs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of ProPhase Labs's Earnings

<h3>Gainers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock moved upwards by 22.7% to $2.7 during Wednesday's after-market session. The market value of their outstanding shares is at $31.0 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock increased by 15.41% to $0.1. The company's market cap stands at $13.5 million. </li>
<li>Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) shares increased by 11.09% to $2.81. The market value of their outstanding shares is at $87.5 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock increased by 10.41% to $0.53. The market value of their outstanding shares is at $16.0 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares rose 7.94% to $1.9. The company's market cap stands at $135.3 million. The company's, Q4 earnings came out today. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares rose 7.19% to $7.6. The market value of their outstanding shares is at $660.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 20.8% to $0.11 during Wednesday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>OSR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSRH#NASDAQ">OSRH</a>) stock fell 12.14% to $3.33. The market value of their outstanding shares is at $64.1 million. </li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) stock fell 9.1% to $10.5. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out today. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares decreased by 8.71% to $0.64. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock fell 8.0% to $1.9. The company's market cap stands at $2.0 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock fell 5.84% to $1.28. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRV

AEON

ALVO

APDN

IMNM

OCEA

OSRH

PTPI

SILO

ZNTL

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) stock rose 300.3% to $3.92 during Tuesday's regular session. The market value of their outstanding shares is at $12.2 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) stock rose 72.19% to $1.92. The company's market cap stands at $13.8 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock rose 31.6% to $0.56. The market value of their outstanding shares is at $17.0 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares increased by 25.71% to $7.95. The market value of their outstanding shares is at $50.7 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock increased by 24.61% to $1.25. The company's market cap stands at $82.1 million. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares rose 21.55% to $7.05. The market value of their outstanding shares is at $334.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock declined by 59.8% to $1.36 during Tuesday's regular session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares declined by 59.27% to $1.56. The company's market cap stands at $26.8 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares declined by 59.05% to $0.17. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares decreased by 33.8% to $7.13. The company's market cap stands at $432.6 million. The company's, Q4 earnings came out today. </li>
<li>Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock decreased by 32.33% to $1.9. The market value of their outstanding shares is at $91.1 million. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) stock decreased by 23.88% to $5.1. The company's market cap stands at $6.6 million. The company's, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BACK

CNSP

CRMD

FBRX

GLTO

IOBT

MURA

POAI

SAVA

TNON

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock increased by 39.2% to $2.06 during Monday's pre-market session. The market value of their outstanding shares is at $1.5 million. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) shares moved upwards by 20.2% to $1.19. The market value of their outstanding shares is at $5.2 million. </li>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) stock rose 19.18% to $2.05. The market value of their outstanding shares is at $2.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares rose 17.94% to $1.7. The market value of their outstanding shares is at $3.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares increased by 17.7% to $69.01. The company's market cap stands at $898.0 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock rose 16.54% to $0.36. The market value of their outstanding shares is at $10.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock declined by 44.1% to $1.0 during Monday's pre-market session. The market value of their outstanding shares is at $26.8 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) shares decreased by 37.0% to $1.15. The market value of their outstanding shares is at $19.3 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares decreased by 32.6% to $0.75. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 13.92% to $4.27. The market value of their outstanding shares is at $49.1 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares decreased by 12.46% to $0.95. The market value of their outstanding shares is at $6.6 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock fell 10.89% to $0.38. The company's market cap stands at $1.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLR

CAPS

HSDT

RNAZ

THAR

WINT

12 Health Care Stocks Moving In Monday's Pre-Market Session

ProPhase Labs shares are trading higher after the company announced it has been partnering with Crown Medical Collections.

General

ProPhase Says Has Been Partnering With Crown Medical Collections To Pursue Uncollected COVID-19 Testing Receivables From Insurance Companies

ProPhase Labs shares are trading higher after the company announced it the appointment of Stuart Hollenshead as COO.

Management

Reported Earlier, ProPhase Labs Announces The Appointment Of Stuart Hollenshead As COO

<h3>Gainers</h3>
<ul>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock increased by 58.3% to $2.01 during Friday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock moved upwards by 55.34% to $0.45. The market value of their outstanding shares is at $8.2 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock increased by 43.69% to $0.15. The company's market cap stands at $8.9 million. </li>
<li>OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) shares increased by 40.2% to $2.79. The market value of their outstanding shares is at $59.2 million. </li>
<li>AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) stock moved upwards by 13.78% to $9.99. The market value of their outstanding shares is at $261.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares increased by 12.85% to $5.18. The company's market cap stands at $9.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares fell 17.3% to $12.78 during Friday's pre-market session. The market value of their outstanding shares is at $102.2 million. </li>
<li>Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) stock fell 16.63% to $3.31. The market value of their outstanding shares is at $187.4 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares decreased by 16.18% to $0.28. The company's market cap stands at $8.6 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 16.09% to $0.63. The company's market cap stands at $5.2 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares decreased by 15.73% to $0.65. The market value of their outstanding shares is at $22.9 million. </li>
<li>NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) shares declined by 15.47% to $10.22. The market value of their outstanding shares is at $305.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

CELZ

DSGN

MBRX

NKGN

NPCE

OSTX

RCEL

TIVC

VRPX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares increased by 85.7% to $0.54 during Friday's pre-market session. The company's market cap stands at $9.8 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock moved upwards by 60.62% to $2.04. The company's market cap stands at $6.8 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock moved upwards by 25.88% to $0.14. The market value of their outstanding shares is at $7.8 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares increased by 22.44% to $5.62. The market value of their outstanding shares is at $9.8 million. </li>
<li>Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) shares rose 15.15% to $16.41. The company's market cap stands at $2.6 billion. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares moved upwards by 11.6% to $0.67. The company's market cap stands at $3.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock declined by 21.1% to $0.61 during Friday's pre-market session. The market value of their outstanding shares is at $21.4 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock decreased by 20.59% to $0.27. The market value of their outstanding shares is at $8.1 million. </li>
<li>Artiva Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>) stock fell 14.97% to $3.41. The market value of their outstanding shares is at $82.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock decreased by 14.42% to $0.5. The company's market cap stands at $2.8 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock fell 14.37% to $0.65. The market value of their outstanding shares is at $5.3 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock declined by 13.22% to $0.52. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARTV

AVGR

CERT

HCTI

MTNB

<h3>Gainers</h3>
<ul>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares rose 64.4% to $0.69 during Thursday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares increased by 41.39% to $0.4. The market value of their outstanding shares is at $11.9 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) stock rose 29.37% to $16.78. The market value of their outstanding shares is at $134.2 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares rose 23.71% to $0.57. The company's market cap stands at $1.8 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares increased by 15.71% to $0.81. The market value of their outstanding shares is at $6.6 million. </li>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares rose 15.38% to $3.14. The market value of their outstanding shares is at $190.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) shares fell 24.6% to $243.0 during Thursday's pre-market session. The market value of their outstanding shares is at $17.5 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares decreased by 23.69% to $0.07. The company's market cap stands at $5.4 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock fell 21.08% to $0.21. The market value of their outstanding shares is at $11.3 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares decreased by 17.57% to $0.24. The company's market cap stands at $7.2 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares decreased by 16.73% to $0.7. The market value of their outstanding shares is at $24.7 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares decreased by 16.17% to $0.14. The company's market cap stands at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

CTCX

OMGA

PLRX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock moved upwards by 60.6% to $0.45 during Thursday's pre-market session. The market value of their outstanding shares is at $13.6 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares rose 25.01% to $0.58. The market value of their outstanding shares is at $1.8 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares rose 22.74% to $0.86. The market value of their outstanding shares is at $7.1 million. </li>
<li>Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) shares moved upwards by 18.0% to $0.37. The company's market cap stands at $6.4 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares increased by 16.54% to $0.71. The company's market cap stands at $24.9 million. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares moved upwards by 13.97% to $1.55. The market value of their outstanding shares is at $21.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock decreased by 26.2% to $0.19 during Thursday's pre-market session. The market value of their outstanding shares is at $10.6 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock decreased by 21.6% to $0.66. The company's market cap stands at $23.3 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares decreased by 12.06% to $0.15. The market value of their outstanding shares is at $1.3 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock declined by 9.79% to $0.16. The company's market cap stands at $5.4 million. </li>
<li>WORK Medical Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOK#NASDAQ">WOK</a>) stock fell 9.1% to $2.2. The company's market cap stands at $32.1 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock decreased by 8.93% to $5.1. The market value of their outstanding shares is at $6.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DHAI

RDHL

Shares of AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter revenue guidance <a href="https://www.benzinga.com/news/earnings/25/02/43676556/applovin-stock-soars-on-q4-earnings-revenue-beat-eps-beat-strong-guidance-and-more">above estimates</a>.
Applovin reported fourth-quarter revenue of $1.37 billion, beating analyst estimates of $1.26 billion, according to Benzinga Pro. The company reported fourth-quarter earnings of $1.73 per share, beating analyst estimates of $1.25 per share.
AppLovin shares jumped 28.9% to $490.10 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Phoenix Motor Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) gained 81.2% to $0.4570 in pre-market trading after the company said third-quarter revenue jumped 1,557% year-over-year to $4.77 million.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) rose 42% to $0.9937 in pre-market trading. Tivic Health Systems shares jumped 198% on Wednesday after the company announced it acquired the exclusive license rights from Statera Biopharma for its Phase III TLR5 agonist entolimod treatment of acute radiation syndrome.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares jumped 45.6% to $0.6701 in pre-market trading.</li>
<li>MGO Global, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) gained 38.5% to $0.6326 in pre-market trading after dipping 24% on Wednesday.</li>
<li>ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) gained 26% to $0.3535 in pre-market following a 7% gain in the previous session.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares climbed 24.6% to $80.72 in pre-market trading following better-than-expected fourth-quarter financial results.</li>
<li>Twin Disc, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWIN#NASDAQ">TWIN</a>) gained 19.4% to $11.99 in pre-market trading after dipping 10% on Wednesday.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) gained 15.6% to $64.72 in pre-market trading after the company reported better-than-expected quarterly financial results.</li>
<li>CEVA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEVA#NYSE">CEVA</a>) gained 8.5% to $34.41 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aspen Aerogels, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NYSE">ASPN</a>) shares fell 30.6% to $8.15 in pre-market trading after the company issued first-quarter guidance below estimates.</li>
<li>The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) dipped 27% to $89.34 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Omega Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) fell 24.6% to $0.1960 in today's pre-market trading after surging 35% on Wednesday. Omega Therapeutics' restructuring committee recently approved a workforce reduction of up to 17 employees for cost-reduction amid a Chapter 11 case and potential asset sale.</li>
<li>NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares fell 24.4% to $0.6363 in pre-market trading. NKGen Biotech shares jumped 122% on Wednesday after the company received FDA Fast Track designation for Troculeucel for the treatment of moderate Alzheimer&#8217;s disease.</li>
<li>Mynaric AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) fell 23.7% to $0.4730 in pre-market trading after jumping 134% on Wednesday.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) shares tumbled 20.6% to $8.00 in pre-market trading. Fastly reported a fourth-quarter loss of 3 cents per share, down from earnings of 1 cent per share in the prior year&#8217;s quarter. Quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate. Fastly expects first-quarter losses of between 9 cents and 5 cents per share, versus the loss of 1 cent estimate, and revenue in a range of $136 million to $140 million, versus the $137.05 million estimate.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) declined 18.1% to $3.30 in pre-market trading.</li>
<li>Atai Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 14.5% to $2.1800 in pre-market trading after the company announced the pricing of public offering of common shares.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 14.1% to $185.94 in pre-market trading after the company reported fourth-quarter results.</li>
<li>Open Lending Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) shares dipped 13% to $5.02 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

ASPN

ATAI

BROS

CEVA

FSLY

HOOD

MGOL

MYNA

RDDT

SLSR

TWIN

Why AppLovin Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares rose 27.4% to $13.5 during Monday's pre-market session. The market value of their outstanding shares is at $702.3 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares rose 25.08% to $0.35. The market value of their outstanding shares is at $15.5 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares moved upwards by 23.0% to $0.44. The market value of their outstanding shares is at $52.6 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares moved upwards by 21.95% to $0.32. The market value of their outstanding shares is at $9.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 15.06% to $0.47. The company's market cap stands at $4.0 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock rose 14.29% to $0.49. The company's market cap stands at $9.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares fell 45.3% to $0.08 during Monday's pre-market session. The market value of their outstanding shares is at $3.2 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares fell 16.29% to $4.01. The company's market cap stands at $232.1 million. </li>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) shares decreased by 14.79% to $4.15. The company's market cap stands at $57.2 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) stock fell 14.38% to $2.74. The market value of their outstanding shares is at $72.2 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) stock fell 13.17% to $5.87. The market value of their outstanding shares is at $113.4 million. </li>
<li>Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) stock fell 12.22% to $4.6. The market value of their outstanding shares is at $173.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ANVS

CUTR

GHRS

HCWB

ICAD

IVVD

NVCT

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

VIRX

Transaction Eliminates More Than $20 Million in Debt, and Other Financial Obligations, Provides $2 million in Cash and Significantly Enhances the Company's Balance Sheet and Liquidity
The Company will review with shareholders at 2:00 p.m. EST, details below.
GARDEN CITY, NY, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today announced the closing of the sale of its wholly-owned subsidiaries, Pharmaloz Manufacturing Inc. and Pharmaloz Real Estate Holdings, Inc. (collectively "Pharmaloz" or "PMI"), to a private equity group based in Houston, Texas ("Buyer" or "Buyers"). The transaction carries an aggregate deal value of approximately $23.6 million and will immediately bolster ProPhase's balance sheet and liquidity by eliminating over $20 million in debt, payables, and other contingent liabilities.
As part of this transformative deal, the Buyers are providing approximately $2 million in cash payments while more than $10 million in debt will be retired. Additionally, the Buyers are assuming nearly $2 million in capital leases and close to $3 million in current and accrued payables, as well as canceling $300,000 in accrued interest tied to the debt being retired. The private equity firm will further assume approximately $3 million of upcoming capital expenditures.
The transaction includes the acquisition of Pharmaloz Real Estate Holdings, with the private equity group assuming the existing $3.3 million mortgage on PMI's manufacturing facility. Several ProPhase employees will transfer to Pharmaloz, thereby reducing the Company's overhead. Overall, the transaction better positions the Company to focus on its highly promising and high value core businesses.

Asset Sales

ProPhase Labs Announces $23.6M Sale Of Pharmaloz Units To Houston Equity Group, Eliminates $20M Debt, Gains $2M Cash

The Company will review on Thursday, December 12th, at 12:00 p.m. EST.
GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today provided updates on several key initiatives.
Securing Low-Interest Rate Financing from a Global Private Equity Fund
ProPhase has secured an agreement with a billion-dollar global private equity fund, providing flexible, low-interest rate debt financing as needed. Based on the current operating plans and financial forecasts, the Company believes that the aforementioned debt financing arrangement will eliminate the necessity for future equity financing in the near term and provides the Company with the strategic freedom to focus on and grow its core businesses until a meaningful liquidity event occurs and/or until the Company achieves profitability. Additionally, ProPhase will explore opportunities with the fund to distribute its ProPhase TK supplements—Legendz XL, Legendz Triple Edge, and the forthcoming Equivir—throughout Asia. Equivir is a clinically tested dietary supplement that serves as an immune booster, both prophylactically and therapeutically.
Pharmaloz Capacity Expansion and Major New Contract
The Company is entering the final phase of contract negotiations with a major lozenge brand. This partnership would fully utilize Pharmaloz's forthcoming high-tech production line #2, set to be one of North America's most advanced lines, offering enhanced automation, efficiency, and energy savings. For Line #1, the Company currently estimates a 12-month forward-looking run rate of $15+ million in revenues and a projected $5+ million in net earnings at Pharmaloz. The new contract, if consummated, would add up to $35 million in additional revenues annually. By late 2025, assuming full utilization of production lines #1 and #2, annualized revenue run-rates may approach $50 million, with projected net earnings of between $8 and $10 million entering 2026.
Strategic Executive Hiring
To support these Pharmaloz growth initiatives, ProPhase has hired Jay Schwartz, a 30-year veteran in the consumer health sector. Mr. Schwartz will play a key role in finalizing the large lozenge contract, overseeing the installation of line #2, and preparing it for full-scale utilization. Furthermore, he will assist the Company as we actively pursue strategic alternatives including a potential sale of Pharmaloz.
Implementing Significant Cost Reductions
ProPhase is finalizing a comprehensive set of cost-saving measures targeting its non-core operations. These efforts are expected to reduce operating expenses by at least $6 million per year without impacting core business units. These cost efficiencies will enable the Company to sharpen its focus on its key subsidiaries. Combined with anticipated revenue and earnings growth at Pharmaloz, and the ramp up of DNA Complete, DNA Expand and ProPhase Supplements, the Company is poised for substantial operational improvements in 2025.
Executive Perspective
"The partnership with this global private equity fund should secure, low-interest rate financing at our disposal, with the goal of eliminating discounted equity offerings in the near-term," said Ted Karkus, CEO of ProPhase Labs. "This capital access provides the foundation we need as we finalize a transformative lozenge contract growing revenues just at Pharmaloz from an estimated $15+ million run rate for 2025 to potentially $50 million for 2026. Hiring Jay Schwartz is just the first step in strengthening our management team to handle the increased scale and profitability. Finally, as we implement our significant cost-saving measures in the coming weeks, we are ensuring the Company's operational alignment for robust performance for not only Pharmaloz but for the entire Company in 2025 and in the years ahead."
The Company will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. Ted Karkus, Chairman &amp; Chief Executive Officer, will present on Thursday, December 12th, at 12:00 p.m. EST.

Pharmaloz Announced Final Contract Negotiations With Major Lozenge Brand; New Partnership Could Add $35M Annually To Revenue By Late 2025, Bringing Total Revenue To $50M With Projected Net Earnings Of $8M-$10M In 2026;  Targets $6M Annual Savings Through Non-Core Operations Cost-Cutting Without Affecting Core Units

Press Releases

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

ProPhase Labs Secures Global Private Equity Backing, Nears Major Lozenge Deal, Adds Seasoned Industry Expert, and Plans Significant Cost-Cutting Measures

ProPhase Labs Announces Closing of $23.6 Million Sale of Pharmaloz Manufacturing to Houston-Based Private Equity Firm

ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables

ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs

Analyst Ratings

Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)

ProPhase Labs to Present at the Investor Summit Virtual on March 11

ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025

ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Athira Pharma

Aytu BioPharma

Comments

ProPhase Labs

ProPhase Labs (PRPH) Opciones

ProPhase Labs (NASDAQ:PRPH) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL